Charline Beguin, Oswin Kwan, Grégory Ehx, Stéphanie Humblet-Baron, Murat Cem Köse, Sophie Dubois, Lorenzo Canti, Justine Courtois, Coline Daulne, Jo Caers, Yves Beguin, Caroline Ritacco, Frédéric Baron
5 min
Regulatory T cells (Tregs) are a promising therapy for preventing graft-versus-host disease (GVHD) after stem cell transplantation. However, their low frequency in blood necessitates ex vivo expansion or activation. While TNF-alpha priming has been shown to enhance Treg function in mouse-to-mouse models, it remains unclear whether this strategy effectively translates to human Tregs in a clinical context. The authors sought to develop a more reliable humanized mouse model to evaluate the in vivo functionality of manipulated human Tregs.
The authors developed the HuCD25neg-PBMC-NSG-Treg model, which involves injecting CD25-depleted human peripheral blood mononuclear cells (PBMCs) into irradiated NSG-HLA-A2/HHD mice to induce GVHD. This model allows for the subsequent infusion of manipulated human Tregs. The researchers used this system to test whether 48-hour TNF-alpha priming of human Tregs—which they first characterized using single-cell RNA sequencing and spectral flow cytometry—would improve their suppressive activity against xenogeneic GVHD compared to unprimed Tregs.
In vitro, TNF-alpha priming significantly altered the Treg transcriptome, upregulating 11 Hallmark pathways including TNF-alpha signaling via NF-kB, IL-6-JAK-STAT3, and mTORC1 signaling. It also increased the expression of activation markers like GARP and CD25. Despite these clear in vitro changes, the in vivo results were disappointing. While Treg infusion successfully engrafted and reduced the proliferation and activation of conventional T cells (Tconv) and CD8+ T-cells, TNF-alpha priming provided no additional benefit in preventing GVHD, reducing weight loss, or improving survival compared to unprimed Tregs.
This study highlights a critical disconnect between in vitro activation signatures and actual in vivo therapeutic efficacy. By developing a model that allows for the tracking of specific infused Treg populations, the authors provide a valuable tool for researchers to validate ex vivo manipulation techniques. The findings serve as a cautionary tale, suggesting that efficient in vitro activation does not always translate to enhanced clinical function, emphasizing the necessity of rigorous in vivo testing before moving new Treg-based therapies to clinical trials.
Introduction Regulatory T cells (Treg)-based therapies are increasingly used for treating autoimmune or graft-versus-host (GVHD) disease. Given their low frequency, several approaches aimed at amplifying them or at increasing their immunosuppressive activities are currently investigated. Unfortunately, the impact of these strategies on human Treg function has remained difficult to assess in vivo . Here, we report the development of a novel humanized mouse model of allogeneic and xenogeneic GVHD intended to characterize the immunosuppressive activity of human Treg in vivo . Methods In this model, GVHD is induced by injecting CD25-depleted HLA-A2 − peripheral blood mononuclear cells (PBMC) into irradiated NSG-HLA-A2-HHD mice. The CD25 + (Treg) fraction is maintained in vitro for 48h during which Treg-promoting treatments can be tested before infusion into mice. We took advantage of this model to investigate whether tumor necrosis factor alpha (TNF-α) priming of Treg would increase their suppressive function and improve their ability at preventing xenogeneic GVHD, after assessing the effect of TNF-α on Treg in vitro . Results In vitro , single cell RNAseq analyses showed that eleven Hallmark pathways, including Interferon response, IL-6-JAK-STAT3 signaling, mTORC1 signaling, and TNF-α signaling via NF-κB, were significantly upregulated in Treg following TNF-α priming. In vivo , Treg infusion resulted in higher Treg levels, lower counts of human cells, lower conventional CD4 + (Tconv) and CD8 + T-cell counts, lower KI67 and HLA-DR expression by Tconv and lower Granzyme B expression by CD8 + T-cells in peripheral blood. No significant impact of TNF-α priming of Treg on survival was observed. Discussion These results emphasize the importance of reliable techniques to assess Treg in vivo as efficient methods to activate them in vitro do not always result in an enhanced function in the in vivo setting. In summary, we present here the development of a novel humanized model of GVHD designed to evaluate the in vivo functionality of human Treg. Taking advantage of that model, we observed that TNF-α priming of human Treg did not increase their suppressive activity in vivo .
Alex: Not at all. When they ran the TNF-alpha primed Tregs through the CD25-depletion model and assessed xenogeneic GVHD outcomes, there was no significant improvement in suppressive potency compared to the unprimed control. The transcriptomic shift didn't translate into functional benefit where it counts—in a living system under inflammatory pressure.
Sam: That's a meaningful disconnect. It suggests that the activation signatures we've been chasing might be dissociated from the actual effector function that matters therapeutically.
Alex: And that's the paper's core argument. The transcriptomic readout isn't wrong, exactly—the cells are genuinely responding to the priming stimulus. But responding transcriptomically and suppressing disease are apparently separable outcomes, and the field has been conflating them. What this model forces is a return to functional endpoints as the primary validation criterion, not a surrogate biomarker that correlates with function under some conditions but not others.
Sam: Which raises an uncomfortable question for a lot of ongoing Treg engineering work—how much of the optimization literature is built on in vitro readouts that haven't been stress-tested this way?
Alex: That's exactly where a careful referee would push back on the broader field, not just this paper. The authors are appropriately measured about their own scope—this is one priming strategy, one xenograft model, one disease context. TNF-alpha priming failing here doesn't indict every activation approach. But the platform itself is the transferable contribution. If you're developing a Treg product and you want to know whether your manufacturing intervention actually works, this model gives you a controlled environment to find out before you're in a clinical trial wondering why your Phase I cohort isn't responding.
Sam: So the headline finding is almost secondary to the methodological case the paper is making.
Alex: I'd put it that way, yes. The negative result on TNF-alpha priming is real and worth knowing—it's a concrete data point against a strategy that had looked attractive. But the load-bearing contribution is the model itself: a background-free xenograft system where in vivo Treg function can be measured without the confound of endogenous populations muddying the attribution. That's the tool the field can pick up and use.
Sam: And the implicit critique is that without something like this, we've essentially been doing product development with one hand tied behind our backs.
Alex: Well put. The gap between what cells do in a flask and what they do in a patient isn't new—it's a known problem in adoptive cell therapy broadly. What this paper adds is a concrete experimental handle on that gap, at least for the Treg context. Whether the model generalizes cleanly to other disease settings or other Treg engineering strategies is an open question, and the authors don't overclaim there. But as a proof-of-concept that the background-depletion approach is technically feasible and informative, the data are clear.
Sam: A useful corrective, then—both for this specific priming strategy and for how the field thinks about validating Treg products more generally.
Alex: That's a fair summary. The negative result earns its place precisely because the model is clean enough to trust it. Thanks for listening to ResearchPod.